BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29668588)

  • 21. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
    Bergeman AT; Wilde AAM; van der Werf C
    Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
    Garabedian L; Verryckt A; Panzer J; De Wolf D
    Acta Paediatr; 2008 Jan; 97(1):127-9. PubMed ID: 18052993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia.
    Inoue YY; Aiba T; Kawata H; Sakaguchi T; Mitsuma W; Morita H; Noda T; Takaki H; Toyohara K; Kanaya Y; Itoi T; Mitsuhashi T; Sumitomo N; Cho Y; Yasuda S; Kamakura S; Kusano K; Miyamoto Y; Horie M; Shimizu W
    Europace; 2018 Oct; 20(10):1675-1682. PubMed ID: 29309601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.
    Arakawa J; Hamabe A; Aiba T; Nagai T; Yoshida M; Touya T; Ishigami N; Hisadome H; Katsushika S; Tabata H; Miyamoto Y; Shimizu W
    Heart Vessels; 2015 Nov; 30(6):835-40. PubMed ID: 25092222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia.
    Yan Y; Tang L; Wang X; Zhou K; Hu F; Duan H; Liu X; Hua Y; Wang C
    Orphanet J Rare Dis; 2023 Dec; 18(1):380. PubMed ID: 38053087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia.
    Bosch C; Campuzano O; Sarquella-Brugada G; Cesar S; Perez-Serra A; Coll M; Mademont I; Mates J; Del Olmo B; Iglesias A; Brugada J; Petersen V; Brugada R
    Forensic Sci Int; 2017 Jan; 270():173-177. PubMed ID: 27988446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A; Davis AM
    Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
    Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N; Harada K; Nagashima M; Yasuda T; Nakamura Y; Aragaki Y; Saito A; Kurosaki K; Jouo K; Koujiro M; Konishi S; Matsuoka S; Oono T; Hayakawa S; Miura M; Ushinohama H; Shibata T; Niimura I
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wall JJ; Iyer RV
    Pediatr Emerg Care; 2017 Jun; 33(6):427-431. PubMed ID: 28570361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ryanodine receptor mutations presenting as idiopathic ventricular fibrillation: a report on two novel familial compound mutations, c.6224T>C and c.13781A>G, with the clinical presentation of idiopathic ventricular fibrillation.
    Paech C; Gebauer RA; Karstedt J; Marschall C; Bollmann A; Husser D
    Pediatr Cardiol; 2014 Dec; 35(8):1437-41. PubMed ID: 24950728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Catecholaminergic polymorphic ventricular tachycardia; possible diagnosis in cases of syncope and sudden death of family members].
    Lieve KV; Wilde AA; van der Werf C
    Ned Tijdschr Geneeskd; 2015; 159():A8205. PubMed ID: 25650029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest.
    Campbell MJ; Czosek RJ; Hinton RB; Miller EM
    Am J Med Genet A; 2015 Sep; 167A(9):2197-200. PubMed ID: 26018045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review.
    Leung J; Lee S; Zhou J; Jeevaratnam K; Lakhani I; Radford D; Coakley-Youngs E; Pay L; Çinier G; Altinsoy M; Behnoush AH; Mahmoudi E; Matusik PT; Bazoukis G; Garcia-Zamora S; Zeng S; Chen Z; Xia Y; Liu T; Tse G
    Life (Basel); 2022 Jul; 12(8):. PubMed ID: 35892906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Priori SG
    Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.